Retrophin Inc. (NASDAQ:RTRX) dropped 1.7% on Friday . The stock traded as low as $15.93 and last traded at $16.07, with a volume of 130,974 shares traded. The stock had previously closed at $16.35.

RTRX has been the topic of several research reports. Zacks Investment Research upgraded shares of Retrophin from a “hold” rating to a “strong-buy” rating and set a $17.00 price target on the stock in a research report on Saturday, May 7th. BMO Capital Markets restated an “outperform” rating and issued a $25.00 price target on shares of Retrophin in a research report on Friday, July 15th. Leerink Swann reiterated a “buy” rating on shares of Retrophin in a research report on Wednesday, May 11th. Finally, JMP Securities reiterated a “buy” rating on shares of Retrophin in a research report on Saturday, July 9th. Two investment analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average price target of $24.20.

The company has a market capitalization of $591.37 million and a PE ratio of 6.54. The stock’s 50 day moving average price is $17.47 and its 200 day moving average price is $16.22.

Retrophin (NASDAQ:RTRX) last announced its earnings results on Thursday, August 4th. The biopharmaceutical company reported $0.07 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.30. The business had revenue of $33.30 million for the quarter, compared to analysts’ expectations of $32.73 million. The company’s revenue for the quarter was up 38.2% on a year-over-year basis. On average, equities research analysts predict that Retrophin Inc. will post $0.09 EPS for the current fiscal year.

In other Retrophin news, EVP Alvin Shih sold 8,750 shares of the firm’s stock in a transaction on Thursday, September 1st. The stock was sold at an average price of $16.24, for a total value of $142,100.00. Following the completion of the sale, the executive vice president now directly owns 158,334 shares of the company’s stock, valued at approximately $2,571,344.16. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Retrophin, Inc is a biopharmaceutical company focused on the development, acquisition and commercialization of therapies for the treatment of serious, catastrophic or rare diseases. It sells three products, including Chenodal (chenodeoxycholic acid), Cholbam (cholic acid) and Thiola (tiopronin). Its Chenodal is approved in the United States for the treatment of patients suffering from gallstones in whom surgery poses an unacceptable health risk due to disease or advanced age.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.